Ulcerative Colitis

A phase III, double blind , placebo controlled study of the efficacy and safety of etrolizumab during induction and maintenance in patients with moderate to severe active ulcerative colitis who are refractory to or intolerant of TNF inhibitors. Patients must be 18 and older with an established UC diagnosis at least 6 months prior to entry into the study. They must be intolerant or refractory to one or two (but no more than two) TNF- inhibitors (Infliximab, Adalimumab, Golimumab) within the previous 5 years. This study lasts 66 weeks with the option to go into the long-term extension study depending on response to treatment.

Communication

Contact Us

Quick Contact

  • This field is for validation purposes and should be left unchanged.


Convenience

Our NYC Locations

232 East 30 Street
New York, NY 10016

233 Broadway
Suite 840
New York, NY 10279

100 Crosby Street
Suite 406
New York, NY 10012